Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Resectable non-small cell lung cancer (NSCLC) carries a high risk of postoperative recurrence, underscoring the need for effective perioperative therapies. This nonrandomized, noncomparative phase 2 trial evaluated neoadjuvant ivonescimab monotherapy (cohort 1) or in combination with chemotherapy (cohort 2), followed by surgery and adjuvant ivonescimab.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
